These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37268829)

  • 61. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.
    Shimamura Y; Iwaya Y; Kobayashi R; Rodriguez de Santiago E; Muwanwella N; Raftopoulos S; Mosko JD; May GR; Kandel G; Kortan P; Marcon N; Teshima CW
    Surg Endosc; 2021 Oct; 35(10):5468-5479. PubMed ID: 32989547
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett's esophagus.
    Canto MI; Shin EJ; Khashab MA; Molena D; Okolo P; Montgomery E; Pasricha P
    Endoscopy; 2015 Jul; 47(7):582-91. PubMed ID: 25826275
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Ma B; Yang S; Li W; Li P
    Front Oncol; 2022; 12():801940. PubMed ID: 35296005
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
    Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
    Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
    Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
    Wong T; Tian J; Nagar AB
    Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
    Tsoi EH; Mahindra P; Cameron G; Williams R; Norris R; Desmond PV; Raftopoulos S; Pavey D; Rattan A; Hourigan LF; Lee R; Bourke MJ; Sidhu N; Singh R; Chan A; Krishnamurthi S; Taylor ACF
    Gastrointest Endosc; 2021 Nov; 94(5):902-908. PubMed ID: 34033852
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus.
    Tofani CJ; Gandhi K; Spataro J; Yoo J; Murphy M; Mohan N; Daitch Z; Shah A; Janowski R; Huntley C; Dabbish N; Keith S; Coben R; Cohen S; Kastenberg D; Infantolino A
    United European Gastroenterol J; 2019 Mar; 7(2):225-229. PubMed ID: 31080607
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer.
    Falk GW; Thota PN; Richter JE; Connor JT; Wachsberger DM
    Clin Gastroenterol Hepatol; 2005 Nov; 3(11):1089-94. PubMed ID: 16271339
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study.
    Sinh P; Anaparthy R; Young PE; Gaddam S; Thota P; Balasubramanian G; Singh M; Higbee AD; Wani S; Gupta N; Rastogi A; Mathur SC; Bansal A; Horwhat JD; Cash BD; Falk GW; Lieberman DA; Vargo JJ; Sampliner RE; Sharma P
    Endoscopy; 2015 Aug; 47(8):669-74. PubMed ID: 25910065
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
    Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
    Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.
    Duits LC; Klaver E; Bureo Gonzalez A; Boerwinkel DF; Ten Kate FJW; Offerhaus GJA; Meijer SL; Visser M; Seldenrijk CA; Krishnadath KK; Schoon EJ; Weusten BLAM; Mallant-Hent RC; Pouw RE; Bergman JJGHM
    Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 29873685
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
    Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
    Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
    Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB; Falk GW; Richter JE
    Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrett's esophagus: a multicenter randomized study.
    van Munster SN; Leclercq P; Haidry R; Messmann H; Probst A; Ragunath K; Bhandari P; Repici A; Munoz-Navas M; Seewald S; Lemmers A; Fernández-Esparrach G; Pech O; Schoon EJ; Kariv R; Neuhaus H; Weusten BLAM; Siersema PD; Correale L; Meijer SL; de Hertogh G; Bergman JJGHM; Hassan C; Bisschops R
    Endoscopy; 2023 Apr; 55(4):303-310. PubMed ID: 36150646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.